Physician profile
Ryan Waddell
NPI 1528232683
$13,192.41
in general payments reported to CMS, 2019-2025
34 companies · $1,003 in 2025
The $1,003 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,217 · 2020: $1,179 · 2021: $1,013 · 2022: $1,511 · 2023: $5,794 · 2024: $1,476 · 2025: $1,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,758 · Education: $3,179 · Travel and Lodging: $1,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,757.61 |
| Education | $3,178.98 |
| Travel and Lodging | $1,336.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,468.94 | 2023-2024 | Ion, Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $1,198.53 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,110.10 | 2019-2025 | Breztri, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $1,081.78 | 2019-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $733.66 | 2019-2025 | Ofev, Jascayd |
| Novartis Pharmaceuticals Corporation | $732.44 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $686.12 | 2020-2024 | Uptravi, Opsumit |
| Genzyme Corporation | $535.01 | 2019-2025 | |
| Genentech USA, INC. | $315.52 | 2019-2024 | Xolair |
| Pulmonx Corporation | $276.02 | 2022-2024 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Insmed, INC. | $232.94 | 2021-2025 | Arikayce |
| Mylan Specialty L.P. | $197.07 | 2019-2022 | |
| Verona Pharma, INC. | $185.23 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $182.26 | 2019-2025 | Capvaxive, Winrevair |
| Axsome Therapeutics, INC. | $161.19 | 2022-2025 | Sunosi |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $149.48 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $117.02 | 2019-2021 | |
| Ethicon INC. | $109.59 | 2019 | |
| Pfizer INC. | $96.62 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $85.24 | 2022-2024 | Acthar, Terlivaz |
| Amgen INC. | $83.33 | 2023-2024 | Tezspire, Tavneos |
| Electromed, INC. | $79.56 | 2019-2021 | |
| Advanced Respiratory, INC | $60.09 | 2019-2021 | |
| Vifor Pharma, INC. | $51.95 | 2025 | Zemaira |
| Alexion Pharmaceuticals, INC. | $37.64 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $34.92 | 2020-2021 | |
| Eisai INC. | $32.66 | 2020-2021 | |
| Harmony Biosciences LLC | $31.40 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $25.16 | 2019-2020 | |
| Optinose US, INC. | $24.71 | 2021 | |
| Galvanize Therapeutics, INC | $23.03 | 2025 | Aliya System |
| Portola Pharmaceuticals, LLC | $18.30 | 2019 | |
| Circassia INC. | $18.29 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Waddell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.